Departments of Pathology.
Surgical Oncology.
Am J Surg Pathol. 2018 May;42(5):578-586. doi: 10.1097/PAS.0000000000001040.
Mucinous cystic neoplasm (MCN) of pancreas is one of the precursor lesions of pancreatic ductal adenocarcinoma. The 5-year disease-specific survival for noninvasive MCNs was 100% and 20% to 60% for those with pancreatic ductal adenocarcinoma arising in a MCN. However, the significance of T1a (≤0.5 cm) and T1b (>0.5 and <1.0 cm) carcinoma arising in MCN as defined by the upcoming American Joint Committee on Cancer, eighth edition is unclear. In this study, we examined 3 cases of MCN with T1a or T1b carcinoma and compared their clinicopathologic characteristics and survival to 46 cases of MCN with low-grade dysplasia (MCN-LGD), 7 cases of MCN with high-grade dysplasia (MCN-HGD), and 7 cases of MCN with advanced invasive carcinoma (T2 or higher T stage). The tumors from all 3 cases were submitted in their entirety in 123, 296, and 200 blocks, respectively. All 3 patients were alive with no recurrence during the follow-up of 20.0, 113.8, and 137.2 months, respectively. Similarly, none of the patients who had MCN with either LGD or HGD had recurrence or died of disease. In contrast, 5 of 7 patients who had MCN with advanced invasive carcinoma had recurrence and later died of disease with a median survival of 22.9 months (P<0.001). Our study showed that MCN with T1a and T1b carcinoma had an excellent prognosis similar to MCNs with LGD or HGD after complete tumor sampling for histologic examination. Our results along with the previous studies suggest that close follow-up, rather than aggressive systemic therapy, may be a better approach for these patients.
胰腺黏液性囊性肿瘤(MCN)是胰腺导管腺癌的前体病变之一。无侵袭性 MCN 的 5 年疾病特异性生存率为 100%,而在 MCN 中发生的胰腺导管腺癌的 5 年疾病特异性生存率为 20%至 60%。然而,即将发布的第八版美国癌症联合委员会定义的 T1a(≤0.5cm)和 T1b(>0.5cm 且<1.0cm)MCN 癌的意义尚不清楚。在本研究中,我们检查了 3 例 T1a 或 T1b 癌的 MCN,并将其临床病理特征和生存情况与 46 例低级别异型增生(MCN-LGD)、7 例高级别异型增生(MCN-HGD)和 7 例高级别异型增生(MCN-HGD)的 MCN 进行比较具有高级别侵袭性癌(T2 或更高 T 期)。这 3 例肿瘤分别在 123、296 和 200 个块中完整送检。所有 3 例患者的随访时间分别为 20.0、113.8 和 137.2 个月,均存活且无复发。同样,MCN-LGD 或 MCN-HGD 患者均无复发或死于疾病。相比之下,7 例 MCN 伴高级别侵袭性癌的患者中有 5 例复发,随后死于疾病,中位生存时间为 22.9 个月(P<0.001)。我们的研究表明,在进行完整的肿瘤组织学检查后,MCN 伴 T1a 和 T1b 癌的预后与 MCN-LGD 或 MCN-HGD 相似。我们的研究结果以及之前的研究表明,对于这些患者,密切随访可能比积极的全身治疗更可取。